JPRN-UMIN000006849已完成2 期
Dendritic cell-based immunotherapy against metastatic melanoma patients - Dendritic cell-based immunotherapy
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Within 28 days after the last treatment against cancer 2. Severe systemic infection, hematostatic dysfunction, and organ disorder 3. Steroid treatment, except used for cerebral decompression 4. Pregnant women 5. Hypersensitivity to DC vaccine 6. Severe immunological disoedres (autoimmune disease, immunosuppression) 7. Multiple cancers 8. Anaphylaxis to synthetic peptides
研究者
相似试验
已完成
1 期
Dendritic cell-based tumor-specific immunotherapy against malignant brain tumor - Phase I clinical trialMalignant brain tumor (malignant glioma)JPRN-UMIN000000914Shizuoka Cancer Center12
尚未招募
不适用
Dendritic cell-based immunotherapy combined with low-dose cyclophosphamide in patients with malignant pleural mesotheliomamesothelioma10035597NL-OMON32554Erasmus MC, Universitair Medisch Centrum Rotterdam10
进行中（未招募）
1 期
Dendritic cell-based immunotherapy for advanced solid tumours of children and young adultsChildren and young adults with advanced solid tumours: relapsed or metastatic sarcomas or central nervous system tumours.EUCTR2013-003632-71-ESClínica Universidad de Navarra/Universidad de Navarra10
未知
1 期
Dendritic cell therapy and intratumor dendritic cell injection therapy using Tumor associated antigen or tumor lysate for patients with advanced and recurrent canceradvanced and recurrent cancerJPRN-UMIN000000775Fukushima Medical University25
已完成
不适用
Dendritic cell-based immunotherapy for ovrian cancer patients.NeoplasmsKCT0000831Asan Medical Center10